Tuesday, May 12, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Europe’s COVID death toll could rise by hundreds of thousands

The COVID-19 pandemic could cost an extra 300,000 lives in Europe, according to a study of the number of people in 19 countries who have been neither infected nor vaccinated.

The study’s models also predict that the pandemic could lead to roughly one million hospitalizations in Europe, some of which would contribute to the projected death toll. But the authors of the analysis point out that their estimates are maximum numbers, which assume that all anti-infection restrictions are lifted and contacts between individuals have returned to their pre-pandemic levels. The analysis was posted as a preprint on the medRxiv server and has not yet been peer reviewed.

Source: Nature

https://www.nature.com/articles/d41586-021-03455-w

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!